(S (NP-SBJ (VBN Increased) (JJ natural) (NN killer) (NN cell) (NN activity)) (VP (VBZ correlates) (PP (IN with) (NP (NP (ADJP-COOD (ADJP (JJ low)) (CC or) (ADJP (JJ negative))) (NN expression)) (PP (IN of) (NP (DT the) (NN (neu HER-2)) (NN oncogene))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NN breast) (NN cancer)))))))) (. .))
(NP (NN BACKGROUND) (. .))
(S (NP-SBJ-22 (NP (VBN Increased) (NN expression)) (PP (IN of) (NP (DT the) (NN (neu HER-2)) (NN oncogene))) (PP (IN in) (NP (NN breast) (NN cancer)))) (VP-COOD (VP (VBZ correlates) (PP (IN with) (NP (VBN decreased) (NN estrogen) (NN receptor) (NN concentration)))) (CC and) (VP (VBZ seems) (S (NP-SBJ (-NONE- *-22)) (VP (TO to) (VP (VB be) (NP-PRD (DT an) (JJ important) (JJ prognostic) (NN factor))))))) (. .))
(S (NP-SBJ (DT The) (NNS authors)) (VP (VBD investigated) (SBAR (IN whether) (S (NP-SBJ (EX there)) (VP (VBZ is) (NP-PRD (NP (DT a) (NN correlation)) (PP (IN between) (NP (NP-COOD (NP (NN (neu HER-2)) (NN expression)) (CC and) (NP (NP (JJ immunologic) (NNS parameters)) (VP (VBG representing) (NP (NN tumor) (NN defense))))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NN breast) (NN cancer)))))))))))) (. .))
(NP (NN METHOD) (. .))
(S-COOD (S (NP-SBJ-23 (DT A) (JJ Western) (NN blot) (NN analysis)) (VP (VBD was) (VP (VBN used) (NP (-NONE- *-23)) (S (NP-SBJ (-NONE- *)) (VP (TO to) (VP (VB investigate) (NP (NN (neu HER-2)) (NN expression)))))))) (, ,) (IN whereas) (S (NP-SBJ-24 (NP (DT a) (NN chromium-release) (NN assay)) (VP (VBG using) (NP (DT the) (NN K562) (NN cell) (NN line)) (PP (IN as) (NP (NN target))))) (VP (VBD was) (VP (VBN used) (NP (-NONE- *-24)) (S (NP-SBJ (-NONE- *)) (VP (TO to) (VP (VB measure) (NP (NP (NP (JJ natural) (NN killer)) (PRN (-LRB- -LRB-) (NP (NN NK)) (-RRB- -RRB-))) (NN cell) (NN activity)))))))) (. .))
(NP (NNS RESULTS) (. .))
(S (PP (IN In) (NP (NP (NNS patients)) (PP (IN with) (NP (NN breast) (NN cancer))))) (, ,) (NP-SBJ (NN NK) (NN cell) (NN activity)) (VP (VBD was) (ADJP-PRD (RB significantly) (JJR higher)) (PP (VBN compared) (PP (IN with) (NP-COOD (NP (NP (NP (NNS patients)) (PP (IN with) (NP (JJ benign) (NNS tumors)))) (PRN (-LRB- -LRB-) (S (NP-SBJ (NN P)) (VP (JJ =) (NP-PRD (CD 0.006)))) (-RRB- -RRB-))) (CC or) (NP (NP (JJ healthy) (NN control) (NNS subjects)) (PRN (-LRB- -LRB-) (S (NP-SBJ (NN P)) (VP (JJ =) (NP-PRD (CD 0.002)))) (-RRB- -RRB-))))))) (. .))
(S (ADVP (RB Moreover)) (, ,) (NP-SBJ (NP (CD 23.3) (NN %)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (NN breast) (NN cancer)))))) (VP (VBD showed) (NP (NP (DT an) (NN overexpression)) (PP (IN of) (NP (NN (neu HER-2)) (NN protein))))) (. .))
(S (PP (IN Within) (NP (NP (DT this) (NN group)) (PP (IN of) (NP (NNS patients))))) (, ,) (NP-SBJ (NN NK) (NN cell) (NN activity)) (VP (VBD was) (ADJP-PRD (ADJP (RB significantly) (JJR lower)) (PRN (-LRB- -LRB-) (NP (QP (CD 45.6) (CC (- +)) (CD 16.1)) (NN %)) (-RRB- -RRB-))) (PP (VBN compared) (PP (IN with) (NP (NP (NP (DT the) (NN group)) (PP (IN with) (NP (DT no) (NN (neu HER-2)) (NN overexpression)))) (PRN (-LRB- -LRB-) (NP (QP (CD 57.3) (CC (- +)) (CD 11.0)) (NN %)) (-RRB- -RRB-)))))) (. .))
(S (NP-SBJ (NN NK) (NN cell) (NN activity)) (VP (VBD did) (RB not) (VP (VB increase) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NN (neu HER-2)) (NN overexpression))))))) (. .))
(S (ADVP (RB Thus)) (, ,) (NP-SBJ (EX there)) (VP (VBD was) (NP-PRD (NP (DT a) (ADJP (RB statistically) (JJ significant)) (NN correlation)) (PP (IN of) (NP (JJ cytolytic) (NN effector) (NN cell) (NN function))) (PP (IN with) (NP-COOD (NP (NP (NP (NN (neu HER-2)) (NN expression)) (PP (IN of) (NP (DT the) (NN tumor)))) (PRN (-LRB- -LRB-) (S (NP-SBJ (NN P)) (VP (JJ =) (NP-PRD (CD 0.003)))) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NP (NN (neu HER-2)) (NN overexpression)) (VP (VBD correlated) (NP (-NONE- *)) (PP (IN with) (NP (DT a) (JJ negative) (NN estrogen) (NN receptor) (NN status))))) (PRN (-LRB- -LRB-) (S (NP-SBJ (NN P)) (VP (JJ =) (NP-PRD (CD 0.005)))) (-RRB- -RRB-))))))) (. .))
(NP (NN CONCLUSION) (. .))
(S (NP-SBJ (DT These) (NNS data)) (VP (VBP add) (NP (JJ further) (NN evidence)) (PP (TO to) (NP (NP (JJ previous) (NNS observations) (SBAR (-NONE- *ICH*-25))) (PP (IN from) (NP (NP (DT the) (NNS authors)) (POS '))) (SBAR-25 (NN laboratory) (S (NP-SBJ-26 (IN that) (JJ certain) (NN tumor)) (VP (NNS characteristics) (VP (MD may) (VP (VB be) (NP (-NONE- *-26)) (PP (VBN associated) (NP (NP (IN with)) (PP (NNS reactions) (NP (NP (IN of) (DT the)) (PP (NN host) (NP (IN with) (NN breast))))))))))))))) (NN cancer))
